Title
Category
Credits
Event date
Cost
  • Depression
  • Major Depressive Disorder
  • Women’s Mental Health
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Participation
$0.00
The new fast-acting antidepressants esketamine, an NMDA receptor antagonist, and positive allosteric modulators of GABAergic neurotransmission brexanolone and zuranolone have created an important and exciting paradigm shift in the treatment of depression.
  • Renal Disease
  • Cardiology
  • 0.25 AMA PRA Category 1 Credit™
  • 0.25 Participation
$0.00
Clinicians have a number of therapeutic agents to choose from when treating T2D at risk of CKD. However, it's important to know how to sequence these therapies in real-world practice.
  • Renal Disease
  • Cardiology
  • 0.25 AMA PRA Category 1 Credit™
  • 0.25 Participation
$0.00
Experts examine a patient case study as a way of translating guideline-based screening recommendations and current therapies that protect T2D patients from CKD progression in real-world practice.
  • Epilepsy
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Participation
$0.00
Neurologists and other clinicians can improve care by identifying individuals who are susceptible to seizure clusters and educating them on rescue therapies and medications.
  • Parkinson Disease
  • 0.25 AMA PRA Category 1 Credit™
  • 0.25 Participation
$0.00
Parkinson’s disease psychosis (PDP) is a nonmotor symptom of Parkinson’s disease (PD) and includes at least 1 symptom of hallucinations, illusions, delusions, or false sense of presence after onset of PD and recurrent/continuous for 1 month or more.
  • Parkinson Disease
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Participation
$0.00
An average of 35% of patients diagnosed with Parkinson’s disease experience Parkinson’s psychosis. Recognition and diagnosis of this nonmotor manifestation is critical in choosing the best treatment strategy and managing these symptoms.
  • Epilepsy
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Participation
$0.00
Treatment standards for neurologists and other clinicians caring for patients with epilepsy with emphasis on understanding epilepsy epidemiology, SUDEP and ILAE Classification updates, and therapeutic strategies.
  • Rett Syndrome
  • Child and Adolescent Psychiatry
  • Movement Disorders
  • Neurology
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
$0.00
Because of the multiple comorbidities associated with Rett syndrome, clinicians are advised to incorporate clinical guidelines that suggest implementing therapeutics with a multidisciplinary approach and with an eye toward new and emerging therapies. 
  • Cardiology
  • Comorbidity
  • Education
  • Integrated Care
  • Medical Conditions
  • Pulmonary Disease
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
$0.00
Pulmonary arterial hypertension requires risk stratification to develop goal-directed treatment plans, including combination therapy targeting multiple pathways.
  • Renal Disease
  • Adherence
  • Cardiology
  • Comorbidity
  • Diagnostic Tools
  • Education
  • Medical Conditions
  • Primary Care
  • Side Effects
  • Weight
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
$0.00
Regular screening of UACR and adding finerenone to SGLT2 inhibitors can greatly impact T2D at risk for CKD. Join faculty as they discuss three patient cases.

Pages